Review Article

Signal Pathways and Markers Involved in Acute Lung Injury Induced by Acute Pancreatitis

Jialin Zhou,1 Pengcheng Zhou,2 Yingyi Zhang1, Guangzhi Wang3, and Zhe Fan1,2

1Department of General Surgery, The Third People’s Hospital of Dalian, Dalian Medical University, Dalian, China
2School of Medicine, Southeast University, Nanjing, China
3Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian, China

Correspondence should be addressed to Guangzhi Wang; wanggz@dmu.edu.cn and Zhe Fan; fanzhe1982@hotmail.com

Received 29 March 2021; Revised 10 July 2021; Accepted 18 August 2021; Published 29 August 2021

Academic Editor: Mark M. Kushnir

Copyright © 2021 Jialin Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Acute pancreatitis (AP) is a common acute abdominal disease with a mortality rate of about 30%. Acute lung injury (ALI) is a common systemic complication of acute pancreatitis, with progressive hypoxemia and respiratory distress as the main manifestations, which can develop into acute respiratory distress syndrome or even multiple organ dysfunction syndrome (MODS) in severe cases, endangering human health. In the model of AP, pathophysiological process of the lung can be summarized as oxidative stress injury, inflammatory factor infiltration, and alveolar cell apoptosis. However, the intrinsic mechanisms underlying AP and how it leads to ALI are not fully understood. In this paper, we summarize recent articles related to AP leading to ALI, including the signal transduction pathways and biomarkers of AP-ALI. There are factors or pathway aggravating ALI, the JAK2-STAT3 signaling pathway, NLRP3/NF-κB pathway, mitogen-activated protein kinase, PKC pathway, neutrophil protease (NP)-LAMC2-neutrophil pathway, and the P2X7 pathway, and there are important transcription factors in the NRF2 signal transduction pathway which could give researchers better understanding of the underlying mechanisms controlling AP and ALI and lay the foundation for finally curing ALI induced by AP.

1. Introduction

Acute pancreatitis (AP) is an acute inflammatory process of the pancreas, which can injure not only local peripancreatic tissue but remote organs and systems as well [1]. The acute inflammatory state of the pancreas usually follows an infection, which may lead to multisystem organ dysfunction, including acute lung injury (ALI) [2–4]. During this pathophysiological process, cytokines and inflammatory mediators are released in large quantities, activating multiple signaling pathways which cause damage to the body. However, the underlying mechanism is not completely clear. In recent years, the signaling pathways mediating the occurrence of severe AP (SAP) have become better known, and it has now been shown that multiple signaling pathways are involved in the biological processes of alveolar endothelial cell proliferation, differentiation, and apoptosis caused by AP. In this paper, we summarize the roles of seven pathways and related biomarkers in AP-ALI which have increased our understanding of the development of the disease and provided novel therapeutic approaches for its treatment.

2. JAK2-STAT3 Signaling Pathway

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway has previously been shown to play a role in tumorigenesis. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that preferentially activates STAT3 and has a role in both initiating and exacerbating the inflammatory process. During inflammation, adhesion molecules, substances expressed on endothelial cells (ECs), contribute to the recruitment and migration of leukocytes to the subendothelial stroma [5].

AP can induce the expression of intercellular adhesion molecule-1 (ICAM-1) through the JAK2/STAT3 signaling pathway, and the induction of ICAM-1 is associated with leukocyte adhesion and migration, leading to amplification of endothelial cell injury and inflammatory response. In
addition, AP can activate IL-6 and tumor necrosis factor (TNF-α), further activating the JAK2/STAT3 pathway, leading to ICAM-1 activation and promoting the upregulation of nuclear factor-κB (NF-κB), which in turn induces the development of ALI [6]. Dexamethasone treatment delays SAP-induced upregulation of TNF-α and NF-κB [7]. Dexamethasone treatment may reduce cytokine production by inhibiting ICAM-1, which may be a cause of its anti-inflammatory effect [6]. IL-6 inhibits proliferation, promotes apoptosis, and contributes to lung injury by activating the JAK2/STAT3 signaling pathway [8–10]. A short mutant peptide of hydrostatin-SN10 (peptide sequence, DEQHLETELH) extracted from snake venom inhibits AP-ALI by inhibiting IL-6 induced by JAK2/STAT3 signaling (Figure 1).

### 3. NLRP3/NF-κB Pathway

Protein 3 (NLRP3) inflammasome is a substance containing NACHT, LRR, and PYD domains that leads to the production of IL-1β and IL-18 by sensing pathogen and danger-related molecular patterns (PAMPs and DAMPs) [11]. NF-κB signaling is an important initial step in initiating NLRP3 activation, and reactive oxygen species (ROS) generated by NF-κB-mediated inflammation are also a risk signal for NLRP3 activation [12]. NLRP3 activation is followed by ASC recruitment, activation of cysteine protease-1 (caspase-1), and induction of pro-IL-1β or pro-IL-18 processing and maturation [13, 14]. Thus, both signals, NLRP3 and NF-κB, act together to induce the activation of cytokines (e.g., IL-1β) that promote ALI.

Lack of functional Toll-like receptor 4 (TLR4) leads to a decreased NF-κB response and reduced production of proinflammatory mediators, ameliorating lung inflammation in mice and alveolar macrophages [15]. In addition, monocytic chemotactic protein-1 (MCP-1) is an important factor that has been shown to induce AP in a direct target of NF-κB [16, 17]. Surfactant protein D (SP-D) inhibits SAP-induced ALI and pancreatic injury. It may do so through a pathway that inhibits the activation of NLRP3, inflammasomes, and NF-κB signaling [18]. Isoflavonopoeitin (ISL), a flavonoid derived from licorice, can inhibit NLRP3 pathway by activating Nrf2, inhibiting NF-κB, and also inhibiting NLRP3 activation [19, 20]. Ethylpyruvate inhibits NF-κB activation and downregulates downstream inflammatory cytokine expression in SAP rats and attenuates severe pancreatitis-associated ALI [21] (Figure 2).

### 4. Mitogen-Activated Protein Kinase (MAPK)

Mitogen-activated protein kinase (MAPK), including P38MAPK, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK), is a member of the serine/threonine kinase family and plays an important role in inflammation, tumorigenesis, cell proliferation, apoptosis, differentiation, and stress responses [22–25]. ERK is activated in response to ischemic injury, such as hemorrhagic shock and stroke, and its activation may lead to cell damage and death [26]. The p38MAPK is an important signal transduction enzyme that regulates gene transcription and translation by transducing extracellular signals into cells and is primarily involved in the release of inflammatory cytokines/mediators in the pathogenesis of inflammatory diseases such as ALI and AP [25, 27]. AP-activated TNF-α induces ALI via p-JNK/MAPK and p-ERK/MAPK in the lung, while
p38MAPK can be activated by a variety of extracellular stimuli, such as inflammatory mediators, heat injury, and ultraviolet light. p38MAPK is activated, and chemokines are increased after hemorrhagic shock and can contribute to the development of ALI [28]. MAPK activation can cause multiorgan dysfunction after hemorrhagic shock (MODS) [29, 30]. Therefore, prevention and control of the MAPK signaling pathway may be an important way to prevent hemorrhagic shock-induced ALI and multiorgan dysfunction. BML-111 blocks phosphorylation of JNK, ERK, and p38MAPK, and SP/NK1R may prevent ALI by regulating LTB4 production.

5. PKC Pathway

Protein kinase C (PKC) is a member of the family of phospholipid-dependent serine/threonine kinases. It consists of at least several isoforms [35, 36]. Conventional PKC alleles (α, βI, βII, and β), novel PKC isoforms (δ, ε, η, and ζ), and other PKC isoforms (λ subclass, γ subclass), as well as four PKC isoforms (α, δ, ε, and ζ), each with a unique activation pattern, have been identified in pancreatic follicular cells [37]. Experimental studies have shown that inflammatory mediators are overproduced and released in the lung through a PKC-dependent pathway [38]. The PKC pathway is an important signaling pathway that can be activated by inflammatory cytokines. src-inhibited C kinase substrate (SSeCKS), a PKC substrate and a major inflammatory response protein that is significantly overexpressed in ALI, selectively binds to signaling proteins such as PKC to disrupt endothelial cell permeability [39]. The PKC pathway regulates cytoskeletal protein activity and endothelial cell barrier function by modulating its downstream substrate SSeCKS. PKC-mediated upregulation of SSeCKS activates F-actin, which leads to NF-κB activation in HPMEC, resulting in ALI [40]. Because rescue of aquaporin 5 (AQP-5) and matrix metalloproteinase 9 (MMP-9) and inhibition of apoptosis may lead to NF-κB attenuation [41], we speculate that NF-κB may be a key mediator of apoptosis, AQP-5/MMP-9, and PKC/SSeCKS/F-actin signaling pathways during AP-induced ALI.

SP regulates LTB4 production via the PKCa/MAPK pathway, which in turn promotes AP-ALI via neutrophil rTEM [42]. LXA4 effectively promotes F-actin remodeling and regulates its expression in pulmonary microvascular endothelial cells both in vivo and in vitro by inhibiting the PKC/SSeCKS signaling pathway [43] (Figure 4).
SAP is a sterile inflammatory condition characterized by the release of large amounts of proinflammatory cytokines from damaged glandular follicle cells [47]. The purinergic receptor P2X7 is a member of the P2X family of ATP-gated cation channels and an important molecule involved in the inflammatory response [48]. Activation of P2X7 stimulates multiple signaling pathways such as reactive oxygen species (ROS), MAPKs, and NF-κB, which produce large amounts of inflammatory mediators [49, 50]. Recent studies have shown that P2X7 can effectively stimulate inflammatory activation of NLRP3 [51–53]. Numerous studies have shown that P2X7R is mainly expressed in rodent pancreatic ductal cells and regulates calcium signaling and ion transport [54–56]. Cabili et al. found evidence that NLRP3 receptors are also expressed in the exocrine glands of animals. Alveoli in the pancreas exhibit low functionality and a marked lack of P2X7 receptors for purinergic receptor signaling, but pancreatic duct cells express high amounts of various P2 receptors, especially P2X7 receptors [57]. In addition, SAP is usually initially aseptic, which predisposes to necrosis of the glandular follicle cells [58]. A sterile inflammatory response mediated by damage-associated molecular patterns (DAMP) released from necrotic glandular follicle cells predisposes animals to pancreatic injury, which acts through plasma membrane P2X7 receptors [59]. In addition, the P2X7/NLRP3 pathway is activated 12 h after pancreatic injury. However, inflammation is largely time-course dependent, suggesting that induction of P2X7 is associated with the severity of pancreatitis (Figure 6).

8. NRF2 Signal Transduction Pathway

The nuclear factor erythroid-2-related factor 2 (Nrf2) pathway is thought to be a survival pathway for the mitigation of oxidative damage. Nrf2 is a protective antioxidant that regulates cellular oxidation and reduction homeostasis, and for oxidative stress, the Nrf2 pathway can be modulated to treat SAP [60–62]. Activation of Nrf2 is an important strategy to inhibit ROS generation and control oxidative stress. Furthermore, Nrf2 is an important regulator in ALI [63–65]. Under basal conditions, Nrf2 is present in the cytoplasm as a component of the cell and binds to Kelch-like ECH-associated protein 1 (Keap1), which is ultimately degraded. However, when organisms are under oxidative stress, Nrf2 dissociates from Keap1, a process that can be achieved through various mechanisms such as oxidative modification of cysteine thiols in classical Keap1 and phosphorylation of specific amino acid residues of Nrf2 through multiple protein kinase pathways [66].

The intracellular energy sensor AMP-activated protein kinase (AMPK) is a kinase which is considered to be upstream of Nrf2 and is of interest because of the relationship with redox homeostasis and energy metabolism [67]. In addition, another mechanism of AMPK-mediated Nrf2 activation may include Akt kinase and glycogen synthase kinase 3 beta (GSK3β) [68]. TNF-α can activate the Nrf2 signaling pathway and its downstream gene HO-1; furthermore, LXA4 in HPMEC, as a potent anti-inflammatory...
and novel antioxidant mediator, can further promote Nrf2 expression. LXA4 may attenuate AP-induced inflammation and ROS by regulating the Nrf2 pathway. When injected intraperitoneally, isoliquiritigenin, with a chalcone structure (4,20,40-trihydroxy chalcone), can treat ALI/Acute Respiratory Distress Syndrome (ARDS) associated with gram-negative bacterial infections by activating Nrf2 (Figure 7).

9. Summary and Outlook

AP leads to the continuous activation of various signaling pathways in ALI, as shown in recent studies; ALI was assessed as shown in the indices listed in Table 1. By inhibiting the transduction of the aggravated AP-ALI pathway and promoting the transduction of the attenuated AP-ALI pathway, the secretion of proinflammatory factors can be reduced, pulmonary edema can be reduced, and certain therapeutic effects can be achieved. The discovery of precise and effective target inhibitors still depends on the study of genes and proteins involved in the pathway, but the study of diagnostic genes and proteomics of inflammatory diseases is still at a preliminary stage. Therefore, ALI induced by sepsis [72], trauma [73], and transfusion [74, 75]. In the future, we plan to analyze the interaction between various proteins and genes to deepen our understanding of the mechanism of inflammatory diseases and provide for effective diagnosis and treatments.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no competing interests.

Authors’ Contributions

Jialin Zhou and Pengcheng Zhou contributed equally to this work.

Acknowledgments

This paper was supported by the National Natural Science Foundation of China (81701965) and Natural Science Foundation of Liaoning Province (20180550116 and 2019-MS-069).

References

[1] K. Ito, Y. Igarashi, T. Mimura et al., “Severe acute pancreatitis with complicating colonic fistula successfully closed using the over-the-scope clip system,” Case reports in gastroenterology, vol. 7, no. 2, pp. 314–321, 2013.
[2] H. Lei, W. Minghao, Y. Xiaonan, X. Ping, L. Ziqi, and X. Qing, “Acute lung injury in patients with severe acute pancreatitis,” The Turkish journal of gastroenterology: the official journal of Turkish Society of Gastroenterology, vol. 24, no. 6, pp. 502–507, 2013.
[3] G. Lippi, M. Valentino, and G. Cervellin, “Laboratory diagnosis of acute pancreatitis: in search of the Holy Grail,” Critical reviews in clinical laboratory sciences, vol. 49, no. 1, pp. 18–31, 2012.
[4] N. Matsuda, J. Nishihira, Y. Takahashi, O. Kemmotsu, and Y. Hattori, “Role of macrophage migration inhibitory factor in acute lung injury in mice with acute pancreatitis complicated by endotoxemia,” American journal of respiratory cell and molecular biology, vol. 35, no. 2, pp. 198–205, 2006.
[5] P. K. Chatterjee, Y. Al-Abed, B. Sherry, and C. N. Metz, “Cholinergic agonists regulate JAK2/STAT3 signaling to suppress endothelial cell activation,” American journal of physiology and mechanical biology, vol. 297, no. 5, pp. C1294–C1306, 2009.
[6] X. Han, Y. Wang, H. Chen et al., “Enhancement of ICAM-1 via the JAK2/STAT3 signaling pathway in a rat model of severe acute pancreatitis-associated lung injury,” Experimental and therapeutic medicine, vol. 11, no. 3, pp. 788–796, 2016.
[7] L. Ramudo, S. Yubero, M. A. Manso, J. Sanchez-Recio, E. Wurawga, and I. De Dios, "Effects of dexamethasone on intercellular adhesion molecule 1 expression and inflammatory response in necrotizing acute pancreatitis in rats," Pancreas, vol. 39, no. 7, pp. 1057–1063, 2010.

[8] J. M. Shieh, H. Y. Tseng, F. Jung, S. H. Yang, and J. C. Lin, "Elevation of IL-6 and IL-33 levels in serum associated with lung fibrosis and skeletal muscle wasting in a bleomycin-induced lung injury mouse model," Mediators of Inflammation, vol. 2019, Article ID 7947596, 12 pages, 2019.

[9] F. Ning, H. Zheng, H. Tian et al., "Research on effect of adiponectin on sepsis-induced lung injury in rats through IL-6/STAT3 signaling pathway," Panminerva medica, vol. 62, no. 3, pp. 184–186, 2020.

[10] X. Y. Wu, F. Tian, M. H. Su et al., "BF211, a derivative of bufalin, enhances the cytotoxic effects in multiple myeloma cells by inhibiting the IL-6/JAK2/STAT3 pathway," International Immunopharmacology, vol. 64, pp. 24–32, 2018.

[11] Y. K. Kim, J. S. Shin, and M. H. Nahm, "NOD-like receptors in infection, immunity, and diseases," Yonsei medical journal, vol. 57, no. 1, pp. 5–14, 2016.

[12] F. G. Bauerfeind, G. Horvath, A. Stutz et al., "Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression," Journal of immunology, vol. 183, no. 2, pp. 787–791, 2009.

[13] D. E. Place and T. D. Kanneganti, "Recent advances in inflammasome biology," Current opinion in immunology, vol. 50, pp. 32–38, 2018.

[14] A. Abderrazak, T. Syrovets, D. Coughie et al., "NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases," Redox biology, vol. 4, pp. 296–307, 2015.

[15] E. H. Joh, W. Gu, and D. H. Kim, "Echinocystic acid ameliorates lung inflammation in mice and alveolar macrophages by inhibiting the binding of LPS to TLR4 in NF-kB and MAPK pathways," Biochemical Pharmacology, vol. 84, no. 3, pp. 331–340, 2012.

[16] G. X. Zhou, X. J. Zhu, X. L. Ding et al., "Protective effects of MCP-1 inhibitor on a rat model of severe acute pancreatitis," Hepatobiliary & pancreatic diseases international, vol. 9, no. 2, pp. 201–207, 2010.

[17] S. L. Deshmale, S. Kremlev, S. Amini, and B. E. Sawaya, "Monocyte chemoattractant protein-1 (MCP-1): an overview," Journal of interferon & cytokine research, vol. 29, no. 6, pp. 313–326, 2009.

[18] J. Yu, L. Ni, X. Zhang, J. Zhang, O. Abdel-Razek, and G. Wang, "Surfactant protein D dampens lung injury by suppressing NLRP3 inflammasome activation and NF-kB signaling in acute pancreatitis," Shock, vol. 51, no. 5, pp. 557–568, 2019.

[19] R. Wang, C. Y. Zhang, L. P. Bai et al., "Flavonoids derived from liquorice suppress murine macrophage activation by up-regulating heme oxygenase-1 independent of Nrf2 activation," International Immunopharmacology, vol. 28, no. 2, pp. 917–924, 2015.

[20] H. Honda, Y. Nagai, T. Matsunaga et al., "Isoliquiritigenin is a potent inhibitor of NLRP3 inflammasome activation and diet-induced adipose tissue inflammation," Journal of leukocyte biology, vol. 96, no. 6, pp. 1087–1100, 2014.

[21] Z. G. Luan, J. Zhang, X. H. Yin, X. C. Ma, and R. X. Guo, "Ethyl pyruvate significantly inhibits tumour necrosis factor-a, interleukin-1β and high mobility group box 1 releasing and attenuates sodium taurocholate-induced severe acute pancreatitis associated with acute lung injury," Clinical and experimental immunology, vol. 172, no. 3, pp. 417–426, 2013.

[22] S. M. Cha, J. D. Cha, E. J. Jang, G. U. Kim, and K. Y. Lee, "Sophoraflavone G prevents Streptococcus mutans_ surface antigen I/II- induced production of NO and PGE2, by inhibiting MAPK-mediated pathways in RAW 264.7 macrophages," Archives of oral biology, vol. 68, pp. 97–104, 2016.

[23] Y. C. Hung, C. C. Hsu, C. H. Chung, and T. F. Huang, "The disintegrin, trimucrin, suppresses LPS-induced activation of phagocytes primarily through blockade of NF-kB and MAPK activation," Naunyn-Schmiedeberg's archives of pharmacology, vol. 389, no. 7, pp. 723–737, 2016.

[24] G. Kong, X. Huang, L. Wang et al., "Astilbin alleviates LPS-induced ARDS by suppressing MAPK signaling pathway and protecting pulmonary endothelial glycocalyx," International Immunopharmacology, vol. 36, pp. 51–58, 2016.

[25] T. T. Cornell, A. Fleszar, W. McHugh, N. B. Platt, A. M. Le Vine, and T. P. Shanley, "Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury," American journal of physiology Lung cellular and molecular physiology, vol. 303, no. 3, pp. L251–L258, 2012.

[26] J. T. Hsu, W. H. Kan, C. M. Hsieh, M. A. Choudhry, K. I. Bland, and I. H. Chaudry, "Role of extracellular signal-regulated protein kinase (ERK) in 17β-estradiol-mediated attenuation of lung injury after trauma-hemorrhage," Surgery, vol. 145, no. 2, pp. 226–234, 2009.

[27] Y. Chen, L. Wang, Q. Kang et al., "Heat shock protein A12B protects vascular endothelial cells against sepsis-induced acute lung injury in mice," Cellular physiology and biochemistry, vol. 42, no. 1, pp. 156–168, 2017.

[28] C. Chen, Y. Wang, Z. Zhang, C. Wang, and M. Peng, "Toll-like receptor 4 regulates heme oxygenase-1 expression after hemorrhagic shock induced acute lung injury in mice: requirement of p38 mitogen-activated protein kinase activation," Shock, vol. 31, no. 5, pp. 486–492, 2009.

[29] A. R. Kochanek, E. Y. Fukudome, Y. Li et al., "Histone Deacetylase Inhibitor Treatment Attenuates MAP Kinase Pathway Activation and Pulmonary Inflammation Following Hemorrhagic Shock in a Rodent Model," The Journal of surgical research, vol. 176, no. 1, pp. 185–194, 2012.

[30] K. Y. Lv, X. Y. Yu, Y. S. Bai et al., "Role of inhibition of p38 mitogen-activated protein kinase in liver dysfunction after hemorrhagic shock and resuscitation," The Journal of surgical research, vol. 178, no. 2, pp. 827–832, 2012.

[31] S. Yu, J. Xie, Y. Xiang et al., "Downregulation of TNF-alpha/TNF-R1 signals by AT-Lipoxin A4 may be a significant mechanism of attenuation in SAP-associated lung injury," Mediators of Inflammation, vol. 2019, Article ID 9019404, 7 pages, 2019.

[32] H. B. Li, G. Z. Wang, J. Gong et al., "BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats," The Journal of surgical research, vol. 183, no. 2, pp. 710–719, 2013.

[33] X. M. Wu, K. Q. Ji, H. Y. Wang et al., "Retracted: microRNA-542-5p protects against acute lung injury in mice with severe acute pancreatitis by suppressing the mitogen-activated protein kinase signaling pathway through the negative regulation..."
of P21-activated kinase 1,” Journal of Cellular Biochemistry, vol. 120, no. 1, pp. 290–304, 2019.

[34] W. Lv, C. Lv, S. Yu et al., “Lipoxin A4 attenuation of endothelial inflammation response mimicking pancreatitis-induced lung injury,” Experimental biology and medicine, vol. 238, no. 12, pp. 1388–1395, 2013.

[35] V. Silei, V. Politi, and G. M. Lauro, “Uridine induces differentiation in human neuroblastoma cells via protein kinase C epsilon,” Journal of Neuroscience Research, vol. 61, no. 2, pp. 206–211, 2000.

[36] I. Gutcher, P. R. Webb, and N. G. Anderson, “The isoform-specific regulation of apoptosis by protein kinase C,” Cellular and molecular life sciences, vol. 60, no. 6, pp. 1061–1070, 2003.

[37] B. Bastani, L. Yang, J. J. Baldassare, D. A. Pollo, and J. D. Gardiner, “Cellular distribution of isoforms of protein kinase C (PKC) in pancreatic acini,” Biochimica et Biophysica Acta, vol. 1269, no. 3, pp. 307–315, 1995.

[38] J. Reibman, A. T. Talbot, Y. Hsu et al., “Regulation of expression of granulocyte-macrophage colony-stimulating factor in human bronchial epithelial cells: roles of protein kinase C and mitogen-activated protein kinases,” Journal of immunology, vol. 165, no. 3, pp. 1618–1625, 2000.

[39] S. Akakura, P. Nochajski, L. Gao, P. Sotomayor, S. Matsui, and I. H. Gelman, “Rb-dependent cellular senescence, multinucleation and susceptibility to oncogenic transformation through PKC. scaffolding by SsCKS/AKAP12,” Cell Cycle, vol. 9, no. 23, pp. 4656–4665, 2010.

[40] B. Shao, C. Li, H. Yang et al., “The relationship between Src-suppressed C kinase substrate and β-1,4 galactosyltransferase-I in the process of lipopolysaccharide-induced TNF-α secretion in rat primary astrocytes,” Cellular and molecular neurobiology, vol. 31, no. 7, pp. 1047–1056, 2011.

[41] P. F. Cezar-de-Mello, A. M. Vieira, V. Nascimento-Silva, C. G. Villela, C. Barja-Fidalgo, and I. M. Fierro, “ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor,” British journal of pharmacology, vol. 153, no. 5, pp. 956–965, 2008.

[42] B. Li, X. Han, X. Ye et al., “Substance P-regulated leukotriene B4 production promotes acute pancreatitis-associated lung injury through neutrophil reverse migration,” International Immunopharmacology, vol. 57, pp. 147–156, 2018.

[43] Z. Shi, W. Ye, J. Zhang et al., “LipoxinA4 attenuates acute pancreatitis-associated acute lung injury by regulating AQP-5 and MMP-9 expression, anti-apoptosis and PKC/SSeCKS-mediated F-actin activation,” Molecular Immunology, vol. 103, pp. 78–88, 2018.

[44] S. Katz, M. Hukkanen, K. Lounatmaa, P. Rousselle, T. Tervo, and I. Virtanen, “Cooperation of isoforms of laminin-332 and tenasin-C during early adhesion and spreading of immortalized human corneal epithelial cells,” Experimental eye research, vol. 83, no. 6, pp. 1412–1422, 2006.

[45] P. Mydel, J. M. Shipley, T. L. Adair-Kirk et al., “Neutrophil Elastase Cleaves Laminin-332 (Laminin-5) Generating Peptides That Are Chemotactic for Neutrophils,” The Journal of biological chemistry, vol. 283, no. 15, pp. 9513–9522, 2008.

[46] C. Xu, J. Zhang, J. Liu et al., “Proteomic analysis reveals the protective effects of emodin on severe acute pancreatitis induced lung injury by inhibiting neutrophil proteases activity,” Journal of Proteomics, vol. 220, p. 103760, 2020.

[47] R. Hoque, A. F. Malik, F. Gorelick, and W. Z. Mehal, “Sterile inflammatory response in acute pancreatitis,” Pancreas, vol. 41, no. 3, pp. 353–357, 2012.

[48] J. M. Sanz, P. Chiozzi, D. Ferrari et al., “Activation of microglia by amyloid [beta] requires P2X7 receptor expression,” Journal of immunology, vol. 182, no. 7, pp. 4378–4385, 2009.

[49] H. Xu, C. Xiong, L. He et al., “Trans-resveratrol attenuates high fatty acid-induced P2X7 receptor expression and IL-6 release in PC12 cells: possible role of P 38 MAPK pathway,” Inflammation, vol. 38, no. 1, pp. 327–337, 2015.

[50] Q. Chen, H. Wu, S. Qin et al., “The P2X7 receptor involved in gp120-induced cell injury in BV2 microglia,” Inflammation, vol. 39, no. 5, pp. 1814–1826, 2016.

[51] A. L. Giuliani, A. C. Sarti, S. Falzoni, and F. Di Virgilio, “The P2X7 receptor-interleukin-1 liaison,” Frontiers in pharmacology, vol. 8, p. 123, 2017.

[52] F. Albalawi, W. Lu, J. M. Beckel, J. C. Lim, S. A. McCaughhey, and C. H. Mitchell, “The P2X7 receptor primes IL-1β and the NLRP3 inflammasome in astrocytes exposed to mechanical strain,” Frontiers in cellular neuroscience, vol. 11, p. 227, 2017.

[53] N. Yue, H. Huang, X. Zhu et al., “Activation of P2X7 receptor and NLRP3 inflammasome assembly in hippocampal glial cells mediates chronic stress-induced depressive-like behaviors,” Journal of Neuroinflammation, vol. 14, no. 1, p. 102, 2017.

[54] Y. S. Kim, Y. M. Lee, T. I. Oh et al., “Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism,” International journal of molecular sciences, vol. 19, no. 10, p. 3127, 2018.

[55] J. W. Han, D. W. Shim, W. Y. Shin et al., “Anti-inflammatory effect of emodin via attenuation of NLRP3 inflammasome activation,” International journal of molecular sciences, vol. 16, no. 12, pp. 8102–8109, 2015.

[56] D. Kim, G. Pertea, C. Trapnell, H. Pimentel, R. Kelley, and S. L. Salzberg, “TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions,” Genome biology, vol. 14, no. 4, p. R36, 2013.

[57] M. N. Cabili, C. Trapnell, L. Goff et al., “Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses,” Genes & development, vol. 25, no. 18, pp. 1915–1927, 2011.

[58] C. Trapnell, A. Roberts, L. Goff et al., “Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks,” Nature protocols, vol. 7, no. 3, pp. 562–578, 2012.

[59] L. Kong, Y. Zhang, Z. Q. Ye et al., “CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine,” Nucleic acids research, vol. 35, suppl_2, pp. W345–W349, 2007.

[60] J. Yao, S. Peng, J. Xu, and J. Fang, “Reversing ROS-mediated neurotoxicity by chlorogenic acid involves its direct antioxidant activity and activation of Nrf2-ARE signaling pathway,” BioFactors, vol. 45, no. 4, pp. 616–626, 2019.

[61] M. Jin, J. Wang, X. Ji et al., “MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma,” Journal of experimental & clinical cancer research, vol. 38, no. 1, p. 136, 2019.

[62] Y. Dai, J. Zhang, J. Xiang, Y. Li, D. Wu, and J. Xu, “Calcitriol inhibits ROS-NLRP3-IL-1β signaling axis via activation of Nrf2-antioxidant signaling in hyperosmotic stress stimulated
human corneal epithelial cells,” *Redox biology*, vol. 21, p. 101093, 2019.

[63] H. Lv, Q. Liu, Z. Wen, H. Feng, X. Deng, and X. Ci, “Xanthohumol ameliorates lipopolysaccharide (LPS)-induced acute lung injury via induction of AMPK/GSK3β-Nrf2 signal axis,” *Redox biology*, vol. 12, pp. 311–324, 2017.

[64] W. Yao, G. Luo, G. Zhu et al., “Propofol activation of the Nrf2 pathway is associated with amelioration of acute lung injury in a rat liver transplantation model,” *Oxidative medicine and cellular longevity*, vol. 2014, Article ID 258567, 9 pages, 2014.

[65] G. Zheng, H. Ren, H. Li et al., “*Lycium barbarum* polysaccharide reduces hyperoxic acute lung injury in mice through Nrf2 pathway,” *Biomedicine & pharmacotherapy = Biomedical & pharmacotherapeutics*, vol. 111, pp. 733–739, 2019.

[66] V. O. Tkachev, E. B. Menshchikova, and N. K. Zenkov, “Mechanism of the Nrf2/Keap1/ARE signaling system,” *Biochemistry. Biokhimia*, vol. 76, no. 4, pp. 407–422, 2011.

[67] A. Peairs, A. Radjavi, S. Davis et al., “Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells,” *Clinical and experimental immunology*, vol. 156, no. 3, pp. 542–551, 2009.

[68] L. Wang, S. Zhang, H. Cheng, H. Lv, G. Cheng, and X. Ci, “Nrf2-mediated liver protection by esculentoside A against acetaminophen toxicity through the AMPK/Akt/GSK3β pathway,” *Free radical biology & medicine*, vol. 101, pp. 401–412, 2016.

[69] X. Liu, Q. Zhu, M. Zhang et al., “Isoliquiritigenin ameliorates acute pancreatitis in mice via inhibition of oxidative stress and modulation of the Nrf2/HO-1 pathway,” *Oxidative medicine and cellular longevity*, vol. 2018, Article ID 7161592, 12 pages, 2018.

[70] B. S. Nasir, C. Landry, A. Menaouar et al., “HSP90 inhibitor improves lung protection in porcine model of donation after circulatory arrest,” *The Annals of thoracic surgery*, vol. 110, no. 6, pp. 1861–1868, 2020.

[71] D. R. Calabrese, E. Aminian, B. Mallavia et al., “Natural killer cells activated through NKG2D mediate lung ischemia-reperfusion injury,” *The Journal of clinical investigation*, vol. 131, no. 3, 2021.

[72] E. Akpinar, Z. Kutlu, D. Kose et al., “Protective effects of idebenone against sepsis induced acute lung damage,” *Journal of investigative surgery*, vol. 2021, pp. 1–9, 2021.

[73] J. M. Leonard, C. X. Zhang, L. Lu et al., “Extrathoracic multiple trauma dysregulates neutrophil function and exacerbates pneumonia-induced lung injury,” *The journal of trauma and acute care surgery*, vol. 90, no. 6, pp. 924–934, 2021.

[74] J. W. Semple, J. Rebetz, and R. Kapur, “Transfusion-associated circulatory overload and transfusion-related acute lung injury,” *Blood*, vol. 133, no. 17, pp. 1840–1853, 2019.

[75] J. W. Semple and R. Kapur, “The contribution of recipient platelets in TRALI: has the jury reached a verdict?,” *Transfusion*, vol. 60, no. 5, pp. 886–888, 2020.